Mutations in the PI3K signaling pathway pose a significant challenge to the efficacy of PI3K inhibitors in cancer therapy, particularly secondary to key components such as the PIK3CA gene and other essential components of the signaling pathway [194]. The gene discussed is PIK3CD; the disease is cancer.